February 22, 2023
5 min watch
Source/Disclosures
Published by:
Disclosures:
Marrazzo reports receiving consulting/advisory fees from Merck.
Marrazzo reports receiving consulting/advisory fees from Merck.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
SEATTLE — In this video, Jeanne M. Marrazzo, MD, MPH, director of the division of infectious diseases at the University of Alabama at Birmingham School of Medicine, talks about PrEP adherence and efficacy in cisgender women.
An analysis of data from more than 6,000 women collected over nearly a decade in sub-Saharan Africa and Asia found that for most, adherence declined over time.
“We obviously need other options for women who want to initiate PrEP — they’re really urgently needed,” said Marrazzo, an Infectious Disease News Editorial Board Member.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Conference on Retroviruses and Opportunistic Infections (CROI)
